Page 474 - 16Neonatal Jaundice_compressed

Neonatal jaundice

Bibliographic Study Type & Number of Intervention & Comparison Dichotomous outcomes Continuous Outcomes Comments
Information Evidence Level Patients/Characteristics (E:C) (Mean:SD: N)
Mean TSB:
305 ± 36micromol/litre
Author: Methodology: N: Group 1: No adverse effects were Mean decrease in TSB:
Zahedpasha Y RCT 40 Phototherapy noted Group 1: -104 ± 29 micromol/litre

Year: Blinding: Inclusion: Group 2: Group 2: -142 ± 26 micromol/litre
2008 Not reported G6PD deficiency, Phototherapy + Clofibrate
Gestation age between 38 and
Country: Randomisation: 41 weeks, Subject in the clofibrate group received a
Iran Not reported Birthweight > 2500 g single oral dose of clofibrate (100 mg/kg
TsB between 256 and body weight)
216
ID: Evidence level: 342 micromol/litre
1 -
Exclusion:
Haemolytic disease,
conjugated
hyperbilirubinaemia,
dehydration, infection,
history of Phenobarbital
intake by mother or infant

Demographics:
Gender (M/F): Not reported
Mean GA: Not reported
Mean BW: 3257 ± 479 g
Age at entry to study:
123 ± 55 hours
Mean TSB:
307 ± 33micromol/litre
Author: Methodology: N: Group 1: No adverse effects were Mean decrease in TSB:
Eghbalian F RCT 60 Phototherapy noted Group 1: -137 ± 45 micromol/litre

Year: Blinding: Inclusion: Group 2: Group 2: -171 ± 30 micromol/litre
2007 Not reported Term, breastfed babies, Phototherapy + Clofibrate
Birthweight > 2500 g,
Country: Randomisation: TsB between 256 and Subject in the clofibrate group received a Mean duration of treatment:
Iran Random numbers 427micromol/litre single dose of clofibrate (100 mg/kg body Group 1: 68.8 ± 21.6 hours
table weight)
214
ID: Exclusion: Group 2: 53.6 ± 15 hours
Evidence level: Congenital anomalies,
1 + Haemolytic disease,
Sepsis,
Dehydration,
Exchange transfusion

Demographics:

310